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Background: Peritoneal dialysis (PD) is a form of renal replacement used for advanced chronic kidney disease. PD
effluent holds a great potential for biomarker discovery for diagnosis and prognosis. In this study a novel approach
to unravelling the proteome of PD effluent based-on dithiothreitol depletion followed by 2D-SDS-PAGE and protein
identification using tandem mass spectrometry is proposed.
Results: A total of 49 spots were analysed revealing 25 proteins differentially expressed, among them many
proteins involved in calcium regulation.
Conclusions: Remarkably, a group of proteins dealing with calcium metabolism and calcium regulation has been
found to be lost through peritoneal dialysate effluent, giving thus a potential explanation to the calcification of soft
tissues in patients subjected to peritoneal dialysis and kidney injury. Comparison of literature dealing with PD is
difficult due to differences in sample treatment and analytical methodologies.
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Proteomics is a powerful technology with high-
throughput capabilities in evaluating complex protein
mixtures from biological samples [1]. Through proteo-
mics it has been possible to establish that certain dis-
eases can be traced from alterations of certain proteins
in plasma [2]. In addition to plasma, there are other bio-
logical fluids that contain proteins and that hold great
potential to be used as indicative of disease, such as
cerebrospinal fluid, pleural, pericardial effusions, urine,
and peritoneal dialysate [3-7]. For example, urine has
been used for studies involving kidney and bladder* Correspondence: hmsantos@fct.unl.pt
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unless otherwise stated.diseases [3,4], whilst peritoneal dialysate has been used
in endometriosis [1], and ovarian cancer [6,7] studies.
The increasing in plasma levels of endogenous or exo-
genous toxins is often associated with diseases [8]. When
there is renal failure, removal of these toxins from blood
circulation can be done by effective methods, as extra-
corporeal blood purification and peritoneal dialysis (PD).
Both methods are mainly used as renal replacement
therapy, as artificial kidney, in patients with end-stage
renal disease and acute kidney injury [9-12].
PD produces a fluid known as peritoneal dialysate
effluent (PDE). PDE can be used for clinical diagnosis as
it contains complement factors, hormones, acute phase
proteins, coagulation factors and apolypoproteins [13-17].
The analysis of PDE by proteomics is relatively recent. As
for the analysis of any complex proteome, the results in
terms of proteins identified is limited by the presence of
the most abundant proteins (MAPs), and for the strategy
followed to circumvent this drawback. The first problemLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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complex proteomes can vary over 10 orders of magnitude
whilst the analytical technologies currently available have
2 to 4 orders of magnitude in dynamic range for pro-
tein detection [2]. Therefore, not all proteins can be
determined only on base on the analytical technologies
available in the laboratory. Different solutions have been
developed to avoid this problem, relaying in the separation
of the MAPs, or in the equalization of protein concentra-
tion of the proteins present in the PDE [18,19]. The aim is
to reduce the concentration of MAPs at levels in which
they do not interfere with the detection of other low-
abundance proteins. Recently, DL-Dithiotreitol (DTT) has
been reported as a cheap and easy way to deplete high
abundance proteins to simplify the protein content in hu-
man serum [20,21]. Whichever the solution adopted, this
manuscript shows that the data reported to date dealing
with the proteome of PDE is somewhat inconsistent, as
from five works compared only one protein was found re-
dundant, this is, the majority of the proteins of interest
identified are not consistently reported. Both, the type of
patients selected as well as the differences in the analytical
procedures might be greatly influencing the results. In the
present work DTT has been used to partially deplete peri-
toneal dialysate effluent with success. A revision of the
proteins found to date in literature dealing with PDE is
also presented and compared with the ones found in this
work. A total of 49 proteins have been identified resulting
in 25 non-redundant proteins.
Results and discussion
Analysis of individual peritoneal dialysate effluent
samples using 2-DE
In the present study, samples of peritoneal dialysate ef-
fluent were collect from six patients from the Complexo
Hospitalario Universitario de Ourense (CHUO). The cli-
nical data of these patients is shown in Table 1. Before
analysis the six samples of peritoneal fluid were depleted
with DTT as described in Section 2.4 and quantified by
Bradford assay (total protein content: P01 4.8 ± 0.3 μg/μL;
P02 5.1 ± 0.2 μg/μL; P03 6.3 ± 0.2 μg/μL; P04 5.3 ±
0.1 μg/μL; P05 4.9 ± 0.2 μg/μL; P06 5.7 ± 0.1 μg/μL;Table 1 Clinical information about the patients tested on this
Age Gender Classification Total time
in PD (days)
Kt/V (s)a
P01 69 M Unknown 96 1.93
P02 80 F Ischemic 45 2.3
P03 88 F Unknown 72 1.5
P04 73 M Diabetes Unknown 1.9
P05 54 M Polycystic 34 2.1
P06 51 M Unknown 38 3
aK dialyzer clearance of urea, t is the dialysis time, V is the volume of distribution osee Figure 1 of Additional file 1: Figure S1SM, for further
details). DTT is usually applied to disrupt intramolecular
and intermolecular disulphide bonds, helping to unfold
proteins rich in such bonds, leading to their precipitation.
As the majority of the most abundant proteins, such as al-
bumin and serotransferin, are reach in disulphide bonds,
they are preferentially depleted, although not totally elimi-
nated. Thus, the visualization of other minor proteins is
allowed whilst major proteins are not totally precipitated
[20,21].
In order to analyze the differences among the patients,
2D gels were carried out by triplicate for each patient. A
total of 100 μg of protein was loaded onto pH 3–10
strips, and then proteins were visualized with CBB. A
representative gel is presented in Figure 1. The 2D gels,
were analysed using Progenesis SameSpots software as
described in Section 2.9, and 49 spots were detected and
analysed (Figure 1B). Gel spots were excised and sub-
jected to in-gel digestion and MALDI-TOF/TOF ana-
lysis. Detailed information on the identified proteins is
given in Additional file 2: Table S1SM and Additional
file 3: Table S2SM. A total of 49 spots were excised and
analysed, rendering 49 identifications, after removing re-
dundancy only 25 different proteins were identified, see
Figure 2. Some proteins, such as Ig kappa chain C region
as well as Fibrinogen beta chain were found in as much
as 7 and 9 spots, respectively. This redundancy can be
linked with the existence of post- translational modifica-
tions (PTMs) or the presence of proteases in the PDE,
which might be responsible for the proteolysis of the
proteins, rendering this way a solution rich in protein
fragments. These two effects would lead to identify the
same protein in different spots. Therefore, and for future
works, it is recommended to collect the PDE with a
cocktail of protease inhibitors as well as the analysis of
PTMs.
The proteins identified, an integrative analysis
An integrate analysis of all proteins identified was per-
formed with Cytoscape (v2.8.3). The protein-protein in-
teraction network was imported from Intact (http://www.
ebi.ac.uk/intact/) [22] and contains 318 proteins and 340study
PETb Alb Ca P PTH Vit. D
(μg/mL) (μg/mL) (μg/mL) (pg/mL)c (ng/mL)
0.84 31 98 61 233 5.09
0.62 30 94 57 237 5.4
0.76 21 91 30 49 <3
- 28 110 26 234 <4
0.75 33 85 59 636 82
0.82 30 78 49 374 7.79
f urea; bPeritoneal equilibrium test; cParathyroid hormone.
Figure 1 2D-GE gels of peritoneal dialysis effluent. (A) Representative 2D-GE gels of peritoneal dialysis effluent of each patient used in the
study. (B) Reference gel with spot annotation. Fist dimension was performed in IPG strips pH 3–10, 7 cm and second dimension was done in
SDS-PAGE 12% acrylamide/bis-acrylamide 37.5:1.
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tify the relevant biological pathways that were altered,
BiMGO [23] was used to find gene ontology (GO) clas-
ses of biological processes that were enriched among the
identified proteins. Thus, the most significant biological
pathways found were, (i) acute inflammatory response,
(ii) response to wounding, (iii) response to stress, (iv)
response to stimulus, (v) regulation of immune system
processes and (vi) phospholipid efflux (see Figure 3).
Comments on some of the most relevant proteins iden-
tified are given below.
Fetuin-A forms soluble complexes with calcium and
phosphate that otherwise would not be soluble in bloodas well as participates in inflammatory response [24-26].
Furthermore, this protein has been identified as a potent
inhibitor of pathological calcification, as mice deficient
in Fetuin-A suffers of systematic calcification of soft tis-
sues [27,28]. In addition to this finding, protein AMBP,
also found, inhibits calcium oxalate crystallization. Both,
Fetuin-A and protein AMBP are involved in calcium re-
gulation. Further to he above proteins it was also found
vitamin-D-binding protein. This proteins is also involved
in the metabolism of calcium. Calcification of soft tissues
is a problem in end-terminal patients with renal failure.
As those proteins above mentioned were found in all
PDEs studied in this work, the loss of such proteins
Figure 2 Comparative level of protein abundance in peritoneal
dialysate effluent.
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calcification of soft tissues in patients subjected to PD.
This is such a serious and important issue that it de-
serves to be dealt with in future research.
The Ig kappa protein found is an antibody, which pre-
sents two types of light chains in humans, the kappa
chain and the lambda chain. Both types are highly corre-
lated in humans, varying the normal ratio of kappa tolambda from 0.26 to 1.65. High levels of these proteins
are correlated with kidney diseases [29]. This protein
has been also linked to inflammatory processes in the
human body. Therefore, its presence in PDE was not un-
expected. This protein could be used as a potential bio-
marker of disease progression as its concentration could
be potentially linked with the status of the patient. Also,
the kappa/lambda ratios might deliver information for
diagnostic purposes, especially if the ratio found in the
PD is linked with the one found in serum.
Retinol-binding protein 4, RET4, and transthyretin
(TTHY) are close correlated. RET4 is the specific carrier
for vitamin A (retinol) in the blood. The RET-VitA com-
plex interacts with TTHY, being thus prevented the loss
of the complex through the kidney glomeruli. The pres-
ence of both proteins in the PDE could indicate a failure
in the formation of the RET-VitA complex in patients
with kidney injury or the loss of the complex trough the
peritoneum, and therefore an explanation to problems
related with levels of vitamin A in the body of such type
of patients is advanced. Also, it would be desirable to
analyse the content of the vitamin A in both serum and
PDE.
Alpha-1-microglobulin (A1M) is a protein that acts
suppressing the heme-group, and it is believed to protect
cell and tissues against the damage induced by high con-
centrations of free hemoglobin in blood [30].
The presence of fibrinogen (alfa and beta chains) may
suggest an excessive loss of this protein through the
peritoneal liquid, which may lead to disturbed function
of fibrinogen and also to bleeding or thromboembolic
complications [28,29].
Alpha 1-antitrypsin, A1AT acts as an inhibitor of pro-
teases, protecting tissues from enzymes of inflammatory
cells. Its deficiency can cause complications such as em-
physema, or chronic obstructive pulmonary disease in
adults and cirrhosis in adults or children [31,32].
Comparison of literature dealing with PDE
The literature available about PDE to date is scarce, and
yet some conclusions can be drawn in advance. First, the
studies developed to date have focused in different types
of PD patients, making difficult a comparison. There is
an urgent need for more oriented studies, i.e. focusing
on one disease. Ideally, such studies should be done by
different research teams and in different countries. Even-
tually, this would help to unravel if progress of renal fail-
ure can be monitored from the protein content of the
PDE. Second, there is also a problem related to the hand-
ling and subsequent sample treatment of the PDE. This
problem is highlighted in Figure 4, where different studies
dealing with PDE are compared. As may be seen, al-
though 2D-GE was used as the main analytical tool in all
the works compared, the number of proteins found in
Figure 3 Gene ontology annotation, the horizontal bars represent the number of protein identified in peritoneal dialysis effluent and
involved in each biological process. The p-value calculated for each biological pathway is shown over the bar. A acute inflammatory response;
B response to wounding; C response to stimulus; D response to stress; E response of immune system process; F phospholipid efflux. In the table
on the right are shown the protein involved in each biological pathway.
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if this happens because of the differences in the type of pa-
tients assessed or in the sample treatment used in each
work or because of both. Most likely, both differences in-
fluence the result.
Conclusions
Through this work it has been demonstrated that the
proteome of the peritoneal dialysis effluent is far fromFigure 4 Venn diagrams - Groups of proteins per article and
mutual proteins between them. (Sritippayawan et al., [33]); (Tyan
et al., [34]); (Wang et al., [35]); (Wang et al., [36]); and the proteins
identified in this work.being well established. A total of 25 proteins differen-
tially expressed have been identified among 6 patients
with PD. It is concluded that studies dealing with PDE
are difficult to compare if the methodology used to treat
the samples and to identify the proteins are not the
same. It has been shown that the DTT-based depletion
method is a cheap alternative to be considered to other
expensive approaches. The most remarkable result found
deals with the lost of proteins trough the PDE related
with the metabolism as well as regulation of calcium in
the human body. This finding might be directly linked
to the calcification of soft tissues, in patients subjected
to PD, and opens new insights into the potential use of




All reagents used were HPLC grade or electrophoresis
grade. Albumin, from bovine serum (BSA), urea, thiourea,
3-[(3-Cholamidopropyl) dimethylammonio]-1- propane-
sulfonate (CHAPS), β-mercaptoethanol, glycerol 86-88%,
bradford reagent, coomassie blue R-250 (CBB), DL-
dithiotreitol (DTT), iodoacetamide (IAA), trypsin sequen-
cing trifluoroacetic acid (TFA), sodium deoxycholate
(DOC) and acrylamide/bis-acrylamide 30% solution
(37.5:1) were purchased from Sigma-Aldrich (St. Louis,
USA). (N, N, N’, N’–tetramethylethylene-diamine
(TMED), ammonium persulphate (APS), glycine were
purchased from NZYTech (Lisbon, Portugal). Ampholytes
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purchased from Fluka (Steinheim, Germany). Hydrochlor-
ide acid (HCl), glacial acetic acid, tris-base, trichloroacetic
acid (TCA), sodium dodecyl sulfate (SDS), methanol,
acetonitrile were purchased from Panreac (Barcelona,
Spain). Bromophenol blue was from Riedel-de Haën.
Agarose and Mineral oil were purchased from Biorad
(Hercules, USA).
Molecular weight marker for gel electrophoresis NZY-
Colour Protein Marker II was purchased from NZYTech
(Lisbon, Portugal). α-Cyano-4-hydroxycinnamic acid puriss
for MALDI-MS from Fluka was used as MALDI matrix.
Samples
Peritoneal dialysate (PD) liquid was collected from six
anonymous patients from the Hospital of Ourense, Spain.
Once taken, the samples were aliquoted in the laboratory
and stored at -80°C until further use. The study was ap-
proved by the ethics committee of Galicia (Spain). The
clinical data of these patients is shown in Table 1.
Apparatus
Protean IEF cell, IPG strips pH 3–10 (7 cm), IEF focus-
ing tray with lid, SDS-PAGE (SDS-Polyacrylamide gel)
electrophoresis cell (model Mini-PROTEAN 3) were
from Bio-Rad, following the manufacturer’s instructions.
The image of the gel after staining was acquired in a
PROPIC II DigiLab Genomic Solutions USA. Protein di-
gestion was done in safe-lock tubes of 1.5 mL from
Eppendorf (Hamburg, Germany). A vacuum concentra-
tor centrifuge model UNIVAPO 150 ECH SpeedVac and
a vacuum pump model UNIJET II were used for sample
drying and sample pre-concentration. A mini incubator
from Labnet was used for gel washing, for protein re-
duction and for protein alkylation steps. The centrifuge
MPW-350 and MPW-65R were from MPW Med. In-
struments. Absorption spectra of samples were recorded
as microliter samples using a NANODROP ND-1000
Spectrophotometer from Thermo Scientific (USA). Pro-
tein identification was done in an Ultraflex II MALDI-
TOF/TOF instrument from Bruker Daltonics.
Protein depletion
All samples were precipitated in triplicate in order to ac-
cess reproducibility of the protocol. Peritoneal dialysate
aliquots of 750 μL were made up to 50 mM DTT. Samples
were incubated until precipitate was observed. The super-
natants were harvested by centrifugation at 14.000×g for
20 minutes at 4°C. The proteins present on the resulting
supernatant were precipitated by DOC/TCA. Briefly sam-
ples were incubated with 0.02% (v/v) DOC for 30 minutes
on ice and then TCA 100% (w/v) were added to a final
concentration of 15% (v/v). Then samples were incubated
2 hours on ice. The protein pellets were harvested bycentrifugation at 14.000×g for 20 minutes at 4°C. Then
pellets were washed 3 times with 200 μL of cooled acetone
to remove TCA. Protein pellets were stored at -80°C for
further processing.
2D gel electrophoresis
The protein pellets obtained after precipitation were solu-
bilized in 200 μL of lysis buffer (7 M urea, 2 M thiourea,
30 mM Tris, 2% (w/v) CHAPS, 0.2% (v/v) ampholytes
pH 3–10 and 50 mM DTT). Samples were sonicated using
a 1 mm diameter probe for 6x10 seconds on ice at 50%
sonication amplitude. Insoluble mater was removed by
centrifugation (20 minutes 14.000×g at 4°C). Protein con-
centration was determined using a Bradford assay. Sam-
ples containing about 150 μg of protein from each patient
were mixed with rehydration buffer (7 M urea, 2 M thio-
urea, 2% (w/v) CHAPS, 0.2% (v/v) ampholytes pH 3–10,
50 mM DTT and traces of bromophenol blue) to obtain a
protein solution of 0.8 μg/μL. Sample loading on IPG-
Strip was carried out following the rehydration loading
method. Briefly, 125 μL of the rehydration buffer contain-
ing 0.8 μg/μL of total protein was slowly delivered as a
stipe of liquid on a strip holder. Then, the protective cover
foil from the IPG strip was removed and placed gel facing
down over the strip of rehydration buffer containing pro-
tein. Then it was covered with 1 mL of mineral oil. IPG
strips were allowed to rehydrate overnight at 20°C. After
rehydration/sample loading gel strips were focused. The
strips were removed from the rehydration tray and the oil
was drained, and then transferred to the focusing tray.
The focusing tray was placed into the PROTEAN IEF Cell.
The focusing was performed at voltage: 4000 Volts, time:
6 h30 minutes, maximum current: 50 μA/gel, Volt-Hours:
10.000 V-hr. When the electrophoresis run finished, the
IPG strips were removed and were incubated with equili-
bration buffer (6 M urea, 75 mM Tris pH 8.8, 20% gly-
cerol (v/v), 2% (w/v) SDS, traces of bromophenol blue) as
follows 15 minutes incubation with 2.5 mL of equilib-
ration buffer containing 2% (w/v) of DTT, followed by
15 minutes incubation with 2.5 mL of equilibration buffer
containing 2.5% (w/v) of IAA. The IPG strips were re-
moved from the equilibration tray and clip briefly into the
graduated cylinder containing the running buffer. The
strip gel was placed side up and onto the back plate of the
SDS-PAGE gel. The IPG well of the gel was overlay with
agarose sealing solution (0.5% w/v prepared with 50 mL of
Lammeli running buffer and traces of bromophenol blue).
After agarose solidification, the electrophoresis was con-
ducted at 200 V (constant voltage), 400 mA, 50 minutes.
Gel staining and image analysis
Finished the gel electrophoresis, the gel was fixed for
30 minutes with 40% (v/v) ethanol and 10% (v/v) acetic
acid and then stained overnight with coomassie brilliant
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(v/v) acetic acid until a clear background was observed.
Gel imaging was carried out with a ProPicII-robot using
14 ms of exposure time and a resolution of 70 μm. Gel
piking were done with the same equipment. Progenesis
SameSpots software (v 4.0, NonLinear Dynamics) was
used for gel alignment, spot detection, spot quantifica-
tion, and normalisation for total spot volume in each
gel. Data were statistically compared using the incorpo-
rated statistical package. Significant between-patients
differences for each protein were calculated using Stu-
dent's t test, considering a p value of < 0.05 as statisti-
cally significant and a volume ratio > 1.5 (increase or
decrease).
In-gel protein digestion
After spot piking the spots were transferred to 0.5-mL
Lo-bind tubes. Gel spots were washed with water and
then with 50% acetonitrile/25 mM Ambic until the blue
color disappears. For protein reduction gel spots were
incubated for 60 min with 10 mM dithiothreitol in
25 mM Ambic at 37°C followed by alkylation at room
temperature in the drack with 55 mM iodoacetamide in
25 mM Ambic. Prior to trypsin digestion, gel spots were
washed with 25 mM Ambic and dehydrated with aceto-
nitrile. Then, 15 μL of trypsin (0.02 μg/μL in Ambic
12.5 mM/9% acetonitrile) was added to the gel spots
and incubated for 60 min on ice. After this time, gel
spots were inspected and all the trypsin solution not
absorbed into the gel were removed and the gels were
covered with 25–50 μL of 12.5 mM Ambic depending
on the spot volume. The samples were incubated 12 h at
37°C. Then 25 μL formic acid 5% (v/v) was added to
quench enzymatic activity. The supernatant was trans-
ferred to new lo-bind tube and the peptides were further
extracted from the gel with 50% acetonitrile/5% formic
acid. Samples were dried-down and stored at -20°C until
MS analysis.
MALDI-TOF-MS/MS analysis
Prior to analysis, samples were ressuspended in 10 μL of
formic acid 0.3% and 1 μL of sample was hand-spotted
onto a MALDI target plate (384-spot ground steel plate)
then 1 μL of a 7 mg/mL solution of a-cyano-4-hydroxy-
cinnamic acid matrix in 0.1% (v/v) TFA and 50% (v/v)
ACN was added and allowed to air dry. The mass spec-
trometer was operated in positive ion mode using a
reflectron, and thus, spectra were acquired in the m/z
range of 600–3500. A total of 500 spectra were acquired
for each sample at a laser frequency of 50 Hz. External
calibration was preformed with the [M +H] +monoiso-
topic peaks of bradykinin 1–7 (m/z 757.3992), angioten-
sin II (m/z 1046.5418), angiotensin I (m/z 1296.6848)
substance P (m/z 1758.9326), ACTH clip 1–17 (m/z2093.0862), ACTH18–39 (m/z 2465.1983) and soma-
tostatin 28 (m/z 3147.4710). Peptide mass fingerprints
(PMF) were searched with MASCOT search engine with
the following parameters: (i) SwissProt Database2012_04
(535698 sequences; 190107059 residues); (ii) molecular
weight of protein: all; (iii) one missed cleavage; (iv) fixed
modifications: carbamidomethylation (C); (v) variable
modifications: oxidation of methionine and (vi) peptide
tolerance up to 50 ppm after close-external calibration.
The significance threshold was set to a minimum of 95%
(p ≤ 0.05). A match was considered successful when pro-
tein identification score is located out of the random re-
gion and the protein analysed scores first.
Additional files
Additional file 1: Figure S1SM. Protein concentration in the peritoneal
dialysate effluents used in the study. Protein concentration was
determined by Bradford assay.
Additional file 2: Table S1SM. Proteins identified in 2D-gels of
peritoneal dialysis effluent.
Additional file 3: Table S2SM. Proteins identified in 2D-gels of
peritoneal dialysis effluent: Mascot Score, protein sequence coverage for
the identified proteins.
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